Pseudoephedrine, PPA reporting provision in "meth" act being discussed by DEA, NDMA.
This article was originally published in The Tan Sheet
Executive Summary
PSEUDOEPHEDRINE, PPA REPORTING EXEMPTION PROVISION in the proposed regulations published by the Drug Enforcement Administration Oct. 7 is one of several topics under discussion between DEA and the Nonprescription Drug Manufacturers Association. The regulations are part of DEA's implementation of the Comprehensive Methamphetamine Control Act ("The Tan Sheet" Oct. 13, p. 14). The discussions may help clarify DEA's intent regarding reporting exemptions for retail distributors of "ordinary" pseudoephedrine and phenylpropanolamine products.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning